Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Romiplostim (Nplate) - Important Safety information from AMGEN Ireland as approved by the Irish Medicines Board
Notice type:
3rd Party Publications
Date:
22/09/2011
Problem Or Issue:
Important safety information from AMGEN Ireland on the risk of disease progression to Acute Myelogenous Leukaemia (AML) with romiplostim (Nplate) use in patients with Myelodysplastic Syndrome (MDS)
Romiplostim (Nplate) - Important Safety Information from AMGEN Ireland
« Back
Date Printed: 16/05/2024